Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 4.99 -4.04% -0.21
SYRS closed down 4.04 percent on Friday, November 15, 2019, on 1.82 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SYRS trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -4.04%
Slingshot Bearish Bearish Swing Setup -4.77%
Pocket Pivot Bullish Swing Setup -4.77%
Spinning Top Other -4.77%
Earnings Movers Other -4.77%
Wide Bands Range Expansion -4.77%
Oversold Stochastic Weakness -4.77%
New 52 Week Low Weakness -0.60%
Earnings Movers Other -0.60%
Wide Bands Range Expansion -0.60%

Older signals for SYRS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Diseases Disease Medication Leukemia Refractory Acute Myeloid Leukemia Immune Mediated Diseases Acute Leukemia High Risk Myelodysplastic Syndrome
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.93
52 Week Low 4.88
Average Volume 261,898
200-Day Moving Average 7.7949
50-Day Moving Average 8.065
20-Day Moving Average 5.3458
10-Day Moving Average 5.16
Average True Range 0.4318
ADX 38.74
+DI 12.9115
-DI 29.0554
Chandelier Exit (Long, 3 ATRs ) 6.7046
Chandelier Exit (Short, 3 ATRs ) 6.1754
Upper Bollinger Band 5.9776
Lower Bollinger Band 4.714
Percent B (%b) 0.22
BandWidth 23.637248
MACD Line -0.8003
MACD Signal Line -0.9341
MACD Histogram 0.1338
Fundamentals Value
Market Cap 131.04 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -2.36
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.46
Resistance 3 (R3) 5.48 5.36 5.38
Resistance 2 (R2) 5.36 5.24 5.34 5.35
Resistance 1 (R1) 5.17 5.17 5.11 5.15 5.33
Pivot Point 5.05 5.05 5.02 5.03 5.05
Support 1 (S1) 4.86 4.93 4.80 4.84 4.65
Support 2 (S2) 4.74 4.86 4.72 4.63
Support 3 (S3) 4.55 4.74 4.60
Support 4 (S4) 4.53